Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q4 2020 Earnings Presentation
11 slides from Adc Therapeutics Sa's earnings presentation, Mar 18, 2021
Slide 1: Innovating Science. Inspiring Hope. Q4/FY 2020 Results
Innovating Science. Inspiring Hope. Q4/FY 2020 Results March 18, 2021
Slide 2: Forward-looking statements
Forward-looking statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 3: Agenda
Agenda 01 Chris Martin FY 2020 Business Overview Chief Executive Officer Jay Feingold R&D Update 02 Chief Medical Officer Jenn Creel Financial Update 03 Chief Financial Officer All + Jennifer Herron Q&A 04 Chief Commercial Officer 3
Slide 4: Significant achievements in 2020
Significant achievements in 2020 Lonca (CD19) § BLA accepted, FDA priority review received, PDUFA date May 21, 2021 § Updated clinical data from LOTIS 2 and LOTIS 3 trials presented at ASH 2020 § Launch preparations ongoing Cami (CD25) § Enrollment completed in pivotal Phase 2 trial in Hodgkin lymph
Slide 5: Advancing launch preparations
LO N CA Advancing launch preparations § Deployed a highly experienced and focused oncology field medical team Medical Affairs § Engaging with thought leaders, academic medical centers and community leaders across the country § Making final preparations with sales force of seasoned oncology professio
Slide 6: Expanding the potential for Lonca
LO N CA Expanding the potential for Lonca Additional trials in 2021 § Pivotal Ph 2 trial in r/r FL § Lonca in multiple combinations in NHL LOTIS 5 § Dose-finding study of Lonca in combination with R-CHOP in 1L Lonca + rituximab DLBCL § Ph 3 trial in combination with rituximab LOTIS 3 § Intended to s
Slide 7: Cami programs progressing
CAMI Cami programs progressing § Enrollment completed with 117 patients Phase 2 § Data presented at ASH 2020 demonstrating encouraging antitumor activity as a Pivotal trial in patients with single agent: ORR of 83%, CRR 38% and no new safety signals relapsed or refractory § Highlights potential to a
Slide 8: Earlier-stage pipeline
Earlier-stage pipeline Preclinical Phase 1a Phase 1b Phase 2 Phase 3 / Status/ Confirmatory Upcoming Milestones ADCT-602 | Targeting CD22 Enrollment ongoing Acute Lymphoblastic Leukemia Plan to initiate Phase 1b ADCT-601 | Targeting AXL combination trial Various Solid Tumors in H2 2021 ADCT-901 | Ta
Slide 9: 2020 Financial Update (in $ millions)
2020 Financial Update (in $ millions) Balance Sheet December 31, 2020 December 31, 2019 Cash and cash equivalents $439.2 $115.6 Statement of Cash Flows Fourth Quarter 2020 Full Year 2020 Net cash used for operating activities $51.7 $168.7 3 Months Ended 12 Months Ended Statement of Operations Decemb
Slide 10: 2021 Anticipated Milestones
2021 Anticipated Milestones Lonca § May 21, 2021: FDA PDUFA date § Mid-2021: U.S. Launch in r/r DLBCL, subject to approval § 1H 2021: § Initiate pivotal Phase 2 in FL § Initiate first line dosing study of Lonca with R-CHOP § Complete enrollment in pivotal Phase 2 Lonca combo with ibrutinib in r/r DL
Slide 11: Innovating Science. Inspiring Hope.
Innovating Science. Inspiring Hope. Q4/ FY 2020 Results